Is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study
Clarithromycin may improve cachexia and survival in non-small cell lung cancer (NSCLC), but adequately controlled data are lacking. This study was undertaken primarily to inform the feasibility and scale of a phase III trial. Eligible consenting patients with stage IV NSCLC and cachexia were to be r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Elsevier
2017
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/48254/ |
| _version_ | 1848797725118693376 |
|---|---|
| author | Awan, Sarah Crosby, Vincent Potter, Vanessa Hennig, Ivo Baldwin, David Ndlovu, Mehluli Paradine, Sharon Wilcock, Andrew |
| author_facet | Awan, Sarah Crosby, Vincent Potter, Vanessa Hennig, Ivo Baldwin, David Ndlovu, Mehluli Paradine, Sharon Wilcock, Andrew |
| author_sort | Awan, Sarah |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Clarithromycin may improve cachexia and survival in non-small cell lung cancer (NSCLC), but adequately controlled data are lacking. This study was undertaken primarily to inform the feasibility and scale of a phase III trial. Eligible consenting patients with stage IV NSCLC and cachexia were to be randomized to receive either clarithromycin 250 mg twice daily or placebo for eight weeks. Aspects of trial feasibility recorded included numbers eligible, approached and recruited, together with adherence and completion of treatment and assessments. Over 6 months, none of 125 patients identified fulfilled the entry criteria. The commonest reasons for ineligibility were the use of an excluded concurrent drug (45, 36%), brain metastases (22, 18%), poor performance status (21, 17%) and current chemotherapy (15, 12%). A phase III trial of clarithromycin using these entry criteria is not feasible in this setting. Other macrolides that have a lower risk of a drug–drug interaction may be more practical to pursue. |
| first_indexed | 2025-11-14T20:08:26Z |
| format | Article |
| id | nottingham-48254 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T20:08:26Z |
| publishDate | 2017 |
| publisher | Elsevier |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-482542020-05-04T19:58:38Z https://eprints.nottingham.ac.uk/48254/ Is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study Awan, Sarah Crosby, Vincent Potter, Vanessa Hennig, Ivo Baldwin, David Ndlovu, Mehluli Paradine, Sharon Wilcock, Andrew Clarithromycin may improve cachexia and survival in non-small cell lung cancer (NSCLC), but adequately controlled data are lacking. This study was undertaken primarily to inform the feasibility and scale of a phase III trial. Eligible consenting patients with stage IV NSCLC and cachexia were to be randomized to receive either clarithromycin 250 mg twice daily or placebo for eight weeks. Aspects of trial feasibility recorded included numbers eligible, approached and recruited, together with adherence and completion of treatment and assessments. Over 6 months, none of 125 patients identified fulfilled the entry criteria. The commonest reasons for ineligibility were the use of an excluded concurrent drug (45, 36%), brain metastases (22, 18%), poor performance status (21, 17%) and current chemotherapy (15, 12%). A phase III trial of clarithromycin using these entry criteria is not feasible in this setting. Other macrolides that have a lower risk of a drug–drug interaction may be more practical to pursue. Elsevier 2017-02 Article PeerReviewed Awan, Sarah, Crosby, Vincent, Potter, Vanessa, Hennig, Ivo, Baldwin, David, Ndlovu, Mehluli, Paradine, Sharon and Wilcock, Andrew (2017) Is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study. Lung Cancer, 104 . pp. 75-78. ISSN 0169-5002 Cachexia; Clarithromycin; Macrolide antibiotics; Non-small cell lung cancer http://www.sciencedirect.com/science/article/pii/S0169500216305773 doi:10.1016/j.lungcan.2016.12.010 doi:10.1016/j.lungcan.2016.12.010 |
| spellingShingle | Cachexia; Clarithromycin; Macrolide antibiotics; Non-small cell lung cancer Awan, Sarah Crosby, Vincent Potter, Vanessa Hennig, Ivo Baldwin, David Ndlovu, Mehluli Paradine, Sharon Wilcock, Andrew Is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study |
| title | Is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study |
| title_full | Is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study |
| title_fullStr | Is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study |
| title_full_unstemmed | Is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study |
| title_short | Is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study |
| title_sort | is clarithromycin a potential treatment for cachexia in people with lung cancer?: a feasibility study |
| topic | Cachexia; Clarithromycin; Macrolide antibiotics; Non-small cell lung cancer |
| url | https://eprints.nottingham.ac.uk/48254/ https://eprints.nottingham.ac.uk/48254/ https://eprints.nottingham.ac.uk/48254/ |